劲方医药-B(02595.HK):GFH375/VS-7375多项国内及海外临床研究取得积极进展,在多种 RAS 突变实体瘤中显示优秀疗效

智通财经
Oct 15
【劲方医药-B(02595.HK):GFH375/VS-7375多项国内及海外临床研究取得积极进展,在多种 RAS 突变实体瘤中显示优秀疗效】智通财经APP讯,劲方医药-B(02595.HK)发布公告,GFH375/VS-7375 (口服 KRAS G12D 抑制剂)多项国内及海外临床研究取得积极进展并公布相关研究的最新数据。目前 GFH375 已获得国内治疗 KRAS G12D 突变型胰腺癌、非小细胞肺癌(NSCLC) 、结直肠癌(CRC)的三项突破性疗法认定(BTD),并进入单药治疗胰腺癌及 NSCLC 两项注册性 III 期研究 。劲方海外合作伙伴 Verastem Oncology(Verastem)预计于今年底开展 VS-7375 多个联用方案(联合抗 EGFR 疗法或化疗)一线治疗 PDAC 的注册性 III 期研究,以无进展生存期(PFS)和客观缓解率 (ORR)为双主要终点、总生存期 (OS)为次要终点,目前已与美国食品药品监督管理局(FDA)就研究方案达成共识。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10